Syneron Medical reports record Q4 revenue growth

Syneron Medical reported its strongest quarter ever with a 2014 fourth-quarter revenue of $74.1 million, up 23.7% compared with $59.9 million in the fourth quarter of 2013 on a pro-forma basis.

“The fourth quarter 2014 was our strongest quarter ever, with robust growth in North American product revenue, driven by the commercial launch of UltraShape [non-invasive body contouring] in the U.S., the global PicoWay [picosecond laser tattoo-removal device] launch, and solid results from our product portfolio and regions,” Amit Meridor, CEO of Syneron, said in a press release.

Total revenue of $255.8 million was up 10.2%, year-over-year, the release stated. There was also a 9.4% increase in non-GAAP operating income to $12.9 million in full-year 2014 compared with full-year 2013.

The company’s fourth-quarter operating loss was $0.2 million, down from $2.2 million during the same period in 2013. Additionally, the company reported a net loss of $1.4 million, or $0.04 per share, compared with $9.7 million, or $0.27 per share, the previous year, according to the release.

Reference: www.investors.syneron.com.